$XNCR

Xencor Inc

Xencor is a clinical-stage biopharmaceutical company headquartered in Pasadena, California. It discovers and develops engineered antibody therapeutics for patients with cancer and autoimmune and inflammatory diseases. Its XmAb protein engineering technologies modify antibody Fc domains and support bispecific and other multi-specific drug candidates, including formats designed to engage multiple targets, enhance immune activity, or extend antibody half-life. Xencor’s wholly owned clinical-stage candidates include XmAb819, XmAb541 and XmAb808 for oncology, and XmAb942, plamotamab and XmAb657 for autoimmune or inflammatory diseases. Xencor advances some candidates in its own clinical studies and works with partners on the development and commercialization of other programs. It earns revenue through licensing, collaboration and partnership arrangements, including upfront and milestone payments and royalties. Three marketed medicines have been developed using its XmAb technologies.

1
0
0
—
$3.6M
RANIERI RICHARD J
0%
See all $XNCR insider activity →

Xencor Director Sold Shares Worth Over $3.1M

Xencor director Richard J. Ranieri sold 81,252 shares of Xencor stock in two transactions, totaling $3.19M. He now directly owns 18,514 shares, according to SEC filings.

XNCR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning XNCR (Xencor Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent XNCR coverage spans financial news, insider activity and earnings.

In the last 30 days, XNCR insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($3.6M). The most active reporter was RANIERI RICHARD J with 2 filings.

What's driving XNCR

AlphAI scores every news story that mentions XNCR with an AI model for sentiment and relevance, and aggregates insider trades from Xencor Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $XNCR

Score

Show Me The Money: Xencor (XNCR) Delivers Triple-Digit Gains, With XENITH-UC Poised For The Next Act

Xencor Inc. (XNCR) shares have surged over 140% since October 2025, reaching a three-year high of $36.50. The company's XmAb protein engineering platform is driving clinical advancements, with promising results from studies on XmAb819 and XmAb942. Key catalysts include upcoming data presentations and regulatory discussions for XmAb819 in advanced clear cell renal cell carcinoma.

$XNCRHighAI 8/10Earnings

Xencor Reports Third Quarter 2026 Financial Results

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xencor Reports Third Quarter 2026 Financial Results -- Updated results for XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma and outline of plans for potential registration-enabling development presented during ESMO -- -- Early dose-escalation data fo

$XNCRHighAI 8/10

Truist raises Xencor stock price target on kidney cancer drug data

Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.

Related tickers